EXCLUSIVE: Getaround Partners With TransUnion To Integrate TruVision Credit Insurance In Marketplace

Car sharing marketplace, Getaround Inc (NYSE: GETR) has entered into a partnership with information and insights company, TransUnion (NYSE: TRU).

Car sharing marketplace, Getaround Inc (NYSE:GETR) has entered into a partnership with information and insights company, TransUnion (NYSE:TRU).

The alliance will bring TransUnion’s TruVision Traditional Auto Insurance to Getaround’s car sharing marketplace.

TransUnion has over 12,000 associates operating in more than 30 countries, providing insights into areas like marketing, fraud, risk and advanced analytics.

The integration is expected to help in better risk assessment and in rewarding good drivers while improving the economics of Getaround.

TruVision Insurance will be integrated with Getaround TrustScore, an artificial intelligence (AI) model which will enhance the accuracy to predict guest driving behavior.

This will help Getaround amplify all existing benefits of Getaround TrustScore to guests and hosts, provide information on carsharing trip pricing and help cut the risk of accidents and insurance claims.

With the proposed model in place, the company expects up to 50% reduction in the insurance and claims costs.

“This will benefit hosts seeking to leverage Getaround as a means to unlock additional sources of income by listing their cars on our platform, and prospective guests looking for a terrific alternative to legacy car rental providers,” said Getaround CEO Sam Zaid.

Price Action: GETR shares are trading higher by 2.98% at $0.45 premarket on the last check Tuesday.

 

 

Total
0
Shares
Related Posts
Read More

MorphoSys Shares Higher Premarket After Co Announced on Tuesday an Upfront Payment of $23M from Novartis for Exclusive Worldwide Rights for Pre-clinical Inhibitors of a Novel Cancer Target

MorphoSys announced on Tuesday, that its fully owned subsidiary Constellation Pharmaceuticals, Inc. has entered into a global licensing agreement with Novartis to research, develop and commercialize its pre-clinical inhibitors of a novel cancer target. This program was added to MorphoSys' research portfolio following its acquisition of Constellation Pharmaceuticals, Inc.

MOR